Crispr Therapeutics First NEWS As we learned from Vertex Pharmaceuticals (VRTX) in an earlier, posted press release about the European approval, Crispr Therapeutics (CRSP) has also announced the same breakthrough . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

European Commission Grants Conditional Marketing to Vertex Pharmaceuticals CASGEVY Tuesday Feb 13, 2024, Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted conditional marketing authorization to CASGEVY (exagamglogene autotemcel ), a CRISPR/Cas9 gene-edited therapy. CASGEVY is being approved for patients 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso . . . This content is for paid …

Madrigal Pharmaceuticals Publication in the New England Journal of Medicine Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial Detailed analyses reinforce the safety profile of resmetirom Resmetirom has the potential to become the first and only medicine approved for NASH; PDUFA date is March 14, 2024 Today, February 8, 2024, Madrigal …

MiNK Therapeutics in the NEWS  Today, February 6, 2024, MiNK Therapeutics (INKT) announced the publication of the results in Nature Communications from phase 1/2 study of agenT-797 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vera Therapeutics to Participate in Guggenheim Healthcare Talks February 2, 2024, Vera Therapeutics, Inc. (VERA) announced that the Company’s management team will participate in the 6th Annual Guggenheim Biotechnology Conference, which is taking place in New York in February 7and Feb 8. Fireside Chat Details: Date: Wednesday, February 7th at 2:00 PM ET The . . . This content is for paid subscribers. Please click here …

Vertex Pharmaceuticals Positive Results for VX-548 Today, Vertex Pharmaceuticals (VRTX) announced positive results from its Phase 3 program for the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double- blind, placebo-controlled, pivotal trials, one following abdominoplasty . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vera Therapeutics Positive Data Announcement Vera Therapeutics (VERA) announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in IgAN. From Vera . . . This content is for paid subscribers. Please click here …

Ionis Pharmaceuticals in the NEWS Ionis Pharmaceuticals (IONS) today announced positive topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE). The trial met its primary endpoint of reduction in the rate of angioedema attacks in patients treated with donidalorsen (80mg) via subcutaneous injection dosed every 4 weeks) or every 8 . . . This content is for paid …

Lexaria Bioscience Extensive Program Designed to Support Commercial Discussions. January 16, 2024, Lexaria Bioscience (LEXX) announced a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with the global pharmaceutical companies. Lexaria Bioscience patented drug delivery technology DehydraTECHTM . . . This content is for paid subscribers. Please click here to subscribe or …

CymaBay Therapeutics in the NEWS CymaBay Therapeutics (CBAY) today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC). Seladelpar is a first-in-class oral, selective PPARδ agonist being investigated for the treatment of patients with primary . . . This content is for paid subscribers. Please click here …

Merck & Invivyd in the NEWS Our post today comprises a premarket drug rejection. An important new approval for Merck's (MRK) Keytruda product, and exciting promising trial results for the firm Invivyd, Inc. (

Editas Medicine and Vertex Pharmaceuticals in the NEWA Today December 13, 2023, Editas Medicine (EDIT) announced that it entered into an agreement with Vertex Pharmaceuticals (

Vertex Pharmaceuticals in the NEWS Today, December 13, 2023, Vertex  Pharmaceuticals (VRTX) announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN). Treatment with all . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Roche in the NEWS From Basel, today, December 5, 2023 - Roche (RHHBY) announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast . . . This content is for paid subscribers. Please click here to …

EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration In today's press release, EyePoint Pharmaceuticals (EYPT) announced positive topline results of its Phase 2 DAVIO 2 trial of EYP . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. (ABBV) and ImmunoGen (IMGN) today announced a definitive agreement under which AbbVie will acquire . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Carlisle Companies Inc and Arcturus Therapeutics in the NEWS Today, November 28, 2023, Global biotechnology leaders Carlisle Companies Inc (CSL) and Arcturus Therapeutics (ARCT) announced that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Immunovant Inc in the NEWS Immunovant, Inc. (IMVT) announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of its product IMVT-1402 in healthy adults. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT . . . This content is for paid subscribers. Please click here to subscribe …

Anavex Life Sciences Granted US Patent Anavex Life Sciences (AVXL) – a development-stage biopharmaceutical company announced that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,813,242 entitled “A273 as a therapeutic for insomnia, anxiety, and agitation.  This patent expands Anavex’s existing patent coverage of ANAVEX®273 (blarcamesine), including U.S. Patent No. 11 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease and Transfusion Dependent Beta Thalassemia Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) granted them conditional marketing authorization for CASGEVYTM (exagamglogene autotemcel ), a CRISPR/Cas9 gene . . . This content is for paid subscribers. Please …